U.S. Next-generation Sequencing Library Preparation Market (2025 - 2033) Size, Share & Trends Analysis Report By Sequencing Type (Targeted Genome Sequencing, Whole Genome Sequencing), By Product, By Application, By End Use, And Segment Forecasts

U.S. Next-generation Sequencing Library Preparation Market Summary

The U.S. next-generation sequencing library preparation market size was estimated at USD 652.2 million in 2024 and is projected to reach USD 1.96 billion by 2033, growing at a CAGR of 13.09% from 2025 to 2033. Rapid advancements in sequencing technologies and bioinformatics have facilitated the detection of DNA variations.

Additionally, the broad adoption of Next-Generation Sequencing (NGS) and Whole-Genome Sequencing (WGS) allows for the simultaneous analysis of numerous genes on a single platform, enhancing the role of DNA sequencing in clinical diagnostics. These developments are anticipated to significantly propel market growth over the forecast period.

Declining Sequencing Costs & Broad Clinical Adoption

In the U.S., dramatically reduced sequencing expenses are a key growth engine. Owing to technological breakthroughs, most notably Illumina’s NovaSeq X platform, per-genome sequencing costs have dropped to approximately $200-$600, down from tens of thousands just a decade ago. This affordability fuels widespread NGS deployment in both research and clinical contexts, particularly in oncology, rare disease diagnostics, and reproductive health. Major payers are now reimbursing cancer panels and prenatal sequencing tests, driving consistent demand for library preparation consumables and kits.

Furthermore, the evolution toward precision medicine is propelling growth in the next-generation sequencing library preparation industry. NGS-based companion diagnostics, liquid biopsy, and pathogen surveillance have seen accelerated uptake in the wake of public health priorities like COVID-19 surveillance, and cancer management remains the largest use case in the U.S. As per the American Cancer Society, in 2024, the U.S. records approximately 2,001,140 new cases of invasive cancer, averaging around 5,480 diagnoses each day. There is also strong demand in drug and biomarker discovery, metagenomics, and single-cell transcriptomics, which require sophisticated extraction and library protocols, particularly in high-throughput biopharma and academic sector environments.

Automation & Workflow Standardization

As sequencing scales across U.S. labs, especially CLIA-certified clinical centers and core research facilities, the demand for automation and reproducibility in library prep has grown sharply. Automated workstations (e.g., Agilent Bravo, Hamilton NGS STAR) and magnetic bead-based extraction systems enhance throughput, reduce manual error, and ensure consistency across samples. Additionally, an increasing emphasis on standardization and quality control, such as nucleic acid quantification, adapter consistency, and low-input compatibility, helps minimize bias in WGS and targeted-Seq applications, critical for clinical-grade data. Thus, it will drive the market growth.

Technological advances in sequencing platforms have been a significant factor driving the growth of the NGS library preparation market. Innovations in sequencing technology have dramatically increased throughput, enabling laboratories to process larger samples simultaneously and generate vast amounts of data quickly and accurately. These improvements have also substantially reduced the cost per genome or transcriptome sequenced, making NGS more accessible to research institutions, clinical labs, and commercial entities.

For instance, in June 2025, SPT Labtech introduced advanced automation and miniaturization solutions. Their firefly and mosquito platforms enable advanced low-volume workflows, enhancing precision and reducing reagent costs. These innovations aim to address the growing challenges of manual library preparation and support scalable, cost-effective genomics research. As sequencing technology becomes more powerful and affordable, compatible library preparation is needed to efficiently handle higher sample volumes without compromising data quality.

Market Concentration & Characteristics

Innovation in the U.S. next-generation sequencing library preparation industry is high, driven by the demand for more efficient, accurate, and scalable solutions. Companies are developing kits tailored for challenging samples like single-cell, FFPE, or cfDNA, along with improvements in barcoding, multiplexing, and low-bias amplification. Integration with automation platforms and advances in tagmentation and transposase-based technologies are helping labs streamline workflows while enhancing data quality.

M&A activity in this space is active, particularly among established sequencing firms and reagent developers aiming to expand their portfolios or enter adjacent markets. For instance, companies like Thermo Fisher and Revvity have pursued acquisitions to enhance their molecular biology and sample prep capabilities. Strategic partnerships between kit developers and automation platform providers are also common, enabling broader market reach and workflow integration.

Regulatory oversight in the U.S. has a growing influence on library preparation products, especially as NGS moves into clinical diagnostics. FDA guidance on In Vitro Diagnostic (IVD) and Laboratory Developed Tests (LDTs) is shaping how kits are validated and marketed. Manufacturers must meet strict quality control and reproducibility standards, particularly for clinical-grade applications, which may increase development timelines but also raise product reliability and adoption.

The industry has seen significant growth in recent years, driven by the increasing number of new products launched for NGS technology. For instance, in October 2024, Twist Bioscience launched the FlexPrep Ultra-High Throughput (UHT) Library Preparation Kit, designed to streamline next-generation sequencing (NGS) workflows for agrigenomics and population genomics applications. This kit incorporates Twist's proprietary Normalization by Ligation (NBL) technology, eliminating time-consuming upfront sample quantification and enabling early pooling of up to 12 samples per reaction. The NGS workstation features automated library preparation capabilities, making it easier for customers to streamline their workflows.

While the U.S. remains the primary market, many companies are expanding globally to tap into the growing demand for genomic solutions. Firms are targeting regulatory approvals and establishing distribution partnerships in Europe, Asia Pacific, and Latin America. U.S.-based players are particularly focused on extending their reach into countries investing in precision medicine and national genomics initiatives, positioning themselves as global leaders in the NGS library preparation industry.

Sequencing Type Insights

The targeted genome sequencing segment dominated the industry in 2024, accounting for 64.06% of total revenue, due to its cost-effectiveness, speed, and clinical relevance. Unlike whole-genome approaches, targeted sequencing focuses on specific genes or genomic regions of interest, making it ideal for applications such as oncology panels, hereditary disease testing, and pharmacogenomics. This targeted approach reduces sequencing costs, improves data interpretation, and allows for high sample throughput, critical for clinical diagnostics and research labs. As demand grows for precision medicine and actionable genomic insights, the need for efficient and scalable library prep solutions tailored to targeted sequencing continues to expand, driving market growth.

The whole genome sequencing (WGS) segment is anticipated to grow significantly during the forecast period. WGS is increasingly used in clinical diagnostics, population genomics, rare disease detection, and cancer research due to its unbiased and high-resolution analysis capabilities. As the cost of sequencing continues to decline and computational tools become more accessible, more institutions are integrating WGS into routine workflows. This growing adoption fuels demand for high-quality, automation-compatible library preparation kits that ensure accuracy, reproducibility, and scalability, making WGS a significant contributor to market expansion.

Product Insights

The reagents and consumables segment dominated the U.S. next-generation sequencing industry with the largest share in 2024. This growth is driven by several key factors, including the rising demand for high-quality, reliable reagents for sample preparation, the expanding use of NGS in genomic research and clinical diagnostics, and ongoing innovations in reagent technologies that enhance workflow efficiency and accuracy. For instance, in February 2024, Integrated DNA Technologies (IDT) partnered with Element Biosciences to introduce specialized xGen NGS adapters, universal blockers, and amplification primers tailored for Element’s AVITI System in the U.S. This collaboration was designed to optimize NGS workflows across DNA, RNA, and methylation applications by enabling efficient hybridization capture and reducing sequencing errors.

The instruments segment is anticipated to grow at the fastest CAGR over the forecast period. Rapid technological advancements, increased R&D investments, and the expanding use of these instruments in clinical diagnostics and drug discovery largely drive the growth of the NGS sequencing instruments segment. In recent years, platforms like Illumina’s Solexa, Thermo Fisher’s SOLiD and Ion Torrent systems, and PacBio’s Sequel have introduced innovative capabilities that support high-throughput functional genomic research. These systems have significantly advanced the field of genomics, offering greater efficiency, accuracy, and scalability-factors that continue to fuel demand and contribute to the segment’s expansion.

Application Insights

The drug & biomarker discovery segment dominated the U.S. next-generation sequencing market with a share of 66.39% in 2024 and is anticipated to grow at the fastest CAGR over the forecast period. Library preparation kits play a crucial role in enabling accurate and high-quality sequencing results from diverse biological samples used in preclinical and clinical studies. The growing emphasis on personalized medicine and the development of targeted therapies have further accelerated the adoption of NGS-based approaches for biomarker validation and drug development. As pharmaceutical and biotech companies expand their genomics-driven pipelines, the demand for robust, efficient, and reproducible library prep solutions continues to rise, driving market growth.

The disease diagnostics segment is anticipated to grow at a significant CAGR during the forecast period. The decreasing cost of technology has significantly increased the utilization of data analysis platforms and NGS software by numerous academic institutions and research centers for their projects requiring data interpretation. For instance, in August 2023, Bio-Rad Laboratories introduced novel RNA sequencing library preparation workflows to expand short-read sequencing platforms' capabilities. These advancements enable accurate analysis of RNA transcript expression, including challenging sample types like formalin-fixed paraffin-embedded (FFPE) tissues, facilitating translational research and clinical diagnostics. By improving access to RNA sequencing, these workflows support the identification of biomarkers and gene expression profiling, contributing to a deeper understanding of gene functions and disease mechanisms. Moreover, the number of experienced professionals handling computational tools and data analysis software has gradually grown in research centers, which is anticipated to boost the revenue of this segment.

End Use Insights

The academic & research institutions segment held the largest market share of 36.02% in 2024. With increasing federal and private funding, these institutions are expanding their use of NGS for studies in genomics, transcriptomics, epigenetics, and metagenomics. Library preparation kits are essential for enabling high-throughput, accurate, and reproducible sequencing results from a wide variety of sample types, including low-input or degraded samples. Additionally, the need for customizable and cost-effective library prep solutions tailored to diverse research goals continues to grow, further fueling demand in this segment of the market.

The pharmaceutical and biotechnology companies segment is anticipated to grow at the fastest CAGR of 14.51% during the forecast period. The pharmaceutical and biotechnology companies use NGS to gain deeper insights into disease mechanisms, identify genetic targets, and stratify patient populations, which enhances the development of personalized therapies. As a result, there is a growing demand for reliable, high-throughput library preparation kits that ensure data quality, scalability, and regulatory compliance. The expanding adoption of genomics in clinical trials and precision medicine initiatives further accelerates the need for advanced library prep solutions in the pharmaceutical and biotech sectors.

Key U.S. Next-generation Sequencing Library Preparation Company Insights

The U.S. next-generation sequencing (NGS) library preparation industry features a highly competitive landscape, driven by prominent players leveraging advanced technologies, extensive service offerings, and strategic partnerships. Leading companies such as Illumina, Agilent Technologies, F. Hoffmann-La Roche, and others hold substantial market shares, supported by their innovation in NGS reagents and consumables, strong distribution capabilities, and broad product portfolios.

Additionally, firms like Thermo Fisher Scientific, QIAGEN, and BD continue to strengthen their market positions by delivering scalable, high-performance solutions tailored to a wide range of applications-from clinical diagnostics to genomic and personalized medicine research. Their ability to meet growing demand for efficient, reliable, and cost-effective library prep workflows has reinforced their leadership across both academic and commercial sectors.

New entrants like Oxford Nanopore Technologies and Pacific Biosciences have expanded their presence in the NGS market by offering unique and disruptive technologies, including portable sequencing platforms and long-read sequencing capabilities. These firms are quickly gaining traction with their innovative products, which provide superior performance in specialized sequencing applications such as metagenomics, single-cell sequencing, and real-time analysis.

Recent Developments

• In April 2025 Watchmaker Genomics announced a significant milestone in advancing comprehensive and reliable automated solutions for next-generation sequencing (NGS) workflows. Through its collaboration with Revvity, fully automated and validated protocols have been developed for all of Watchmaker’s DNA and RNA library preparation kits on the Sciclone G3 NGSx liquid handling workstation, positioning Revvity as the first provider to automate the entire library preparation portfolio from Watchmaker.

• In February 2025, Roche’s groundbreaking Sequencing by Expansion (SBX) technology marks a significant advancement in next-generation sequencing (NGS), playing a crucial role in unraveling the genetic foundations of complex diseases such as cancer, immune disorders, and neurodegenerative conditions.

• In October 2024, Twist Bioscience launched the FlexPrep Ultra-High Throughput Library Preparation Kit designed for agrigenomics and population genomics applications.

U.S. Next-generation Sequencing Library Preparation Market Report Scope

U.S. Next-generation Sequencing Library Preparation Market Report Segmentation

This report forecasts revenue growth at the country level and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. next-generation sequencing library preparation market report based on sequencing type, product, application, end use, and region:

• Sequencing Type Outlook (Revenue, USD Million, 2021 - 2033)

  • Targeted Genome Sequencing

  • Whole Genome Sequencing

  • Whole Exome Sequencing

  • Other Sequencing Types

• Product Outlook (Revenue, USD Million, 2021 - 2033)

  • Reagents & Consumables

    • DNA Library Preparation Kits

    • RNA Library Preparation Kits

    • Other Reagents & Consumables

  • Instruments

• Application Outlook (Revenue, USD Million, 2021 - 2033)

  • Drug & Biomarker Discovery

  • Disease Diagnostics

    • Cancer Diagnostics

    • Reproductive Health Diagnostics

    • Infectious Disease Diagnostics

    • Other Disease Diagnostic Applications

  • Others

• End Use Outlook (Revenue, USD Million, 2021 - 2033)

  • Hospitals and Clinics

  • Academic and Research Institutions

  • Pharmaceutical and Biotechnology Companies

  • Others